p3Ysh-3, a peptide inhibitor targeting the STEP Phosphatase-GluA2 AMPA receptor interaction, exhibits a Ki of 1.09 μM. It effectively reverses memory deficits and demonstrates anxiolytic and antidepressant effects in scopolamine-treated rat models, positioning itself as a promising lead compound for the development of novel cognitive enhancers and behavioral modulators [1].